SavedAdd your journal

Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2003 / Cilt: 56 - Sayı: 3

The effectiviness and safety of terazosine for the symptomatic treatment of benign prostatic hyperplasia (Double blind controlled study)

Benign prostat hiperplazisi'nin semptomatik tedavisinde terazosinin etkinliği ve güvenilirliği (Çift kör plesebo kontrollü çalışma)

Ahmet KİPER
M. Abdurrahim İMAMOĞLU
Adnan GÜCÜK
Can TUYGUN
Pages
165–170
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: in the terazosine group, maximal and mean urinary flow rates increased significantly (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: in this study, we aimed to compare effectiveness and side effects of terazosine versus placebo for treatment of urinary symproms due to BPH.
📊
Key Findings & Data:Materials and Methods: 60 patients with infravesical obstructive complaints due to benign prostatic hyperplasia participated in this double-blind parallel study. 30 patients were randomized to placebo group and 30 patients to terazosine group, which is an alpha-1 adrenergic receptor blocker, and the results of both groups vvere compared.
💡
Conclusion & Impact:Results: in the terazosine group, maximal and mean urinary flow rates increased significantly (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: in this study, we aimed to compare effectiveness and side effects of terazosine versus placebo for treatment of urinary symproms due to BPH. Materials and Methods: 60 patients with infravesical obstructive complaints due to benign prostatic hyperplasia participated in this double-blind parallel study. 30 patients were randomized to placebo group and 30 patients to terazosine group, which is an alpha-1 adrenergic receptor blocker, and the results of both groups vvere compared. Results: in the terazosine group, maximal and mean urinary flow rates increased significantly (p

Özet

Amaç: Bu çalışmada, benign prostat hiperplazisi nedeniyle gelişen üriner semptomaları tedavi etmek için bir alfa antagonist olan terazosinin etkinliğini ve yan etkilerini plasebo ile karşılaştırmayı amaçladık. Materyal ve Metod: Benign prostat hiperplazisine bağlı infravezikal obstrüktif şikayetleri olan 60 hastanın 30'una plesebo diğer 30'una selektif-alfa-l adrenerjik reseptör blokörü olan terazosin verilerek çift kör paralel bir çalışma yapıldı ve sonuçları değerlendirildi. Bulgular: Terazosin verilen hastalarda maksimum ve orta-lama idrar akım hızı istatistiksel olarak anlamlı bir artış gösterdi (P

🔖

Cite This Article

KİPER, A., İMAMOĞLU, M. A., GÜCÜK, A., TUYGUN, C. (2022). The effectiviness and safety of terazosine for the symptomatic treatment of benign prostatic hyperplasia (Double blind controlled study). Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 56 - Sayı: 3, 165–170. https://ajindex.com/articles/444114

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Abrams P. objective Evaluation of Bladder Outler Obstruction. Br J.Urol 1995; 76:11
  2. Berry SJ, Coffey OS, Walsh PC, et al. The Development Of Human Benign Prostatic Hyperplasia With Age. J Urol 1984; 132:474
  3. Isaacs JT, Coffey DS. Etiology and Disease Process of Benign Prostatic Hyperplasia. Prostate 1989; 2:33
  4. Mudiyala R, Ahmed A. Effect of Terazosin on Clinical Benign Prostatic Hyperplasia in older adults. Division of Gerontology and Geriatric. Medicine, School of Medicine, University of Alabama of Birmingham, USA. J Am Geriatr. Soc.2003; 51:424-6
  5. Mebust WK, Holtgrewe HL, Cockett ATK, et al. Transurethral prostatectomy: immediate and post- operati ve complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; 141:243
  6. De Campos Feire G. BPH: The basis of pharmaco- logical treatment. Non-Surgical Treatment of BPH (Fizpatrick JM, ed) London, Churchill Livingstone. 47,1992
  7. Beduschi MC, Beduschi R, Oesterling JE. Alpha- blochade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha-1a adrenergic antagonist. Urology 1998; 51:861-72
  8. Tanaka Y, Masumari N, Itoh N, Sato Y, Takahashi A, Ogura H, Furuya S, Tsukamoto T. Urodynamic effects of Terazosin treatment for japanase patients with symptomatic benign prostatic hyperplasia Department of Urology, Sapporo Medical University School of Medicjne, Sapporo Japan. J Urol.2002; 167:2492-5
  9. Kobayashi S, Tang R, Shapiro E, et al. Characterisation and localization of prostaic alphal adrenoceptors using radiologiand receptor binding on slide mounted tissue section. J Urol 1993; 150: 2002
  10. Speakman Mj, Brading AF, Gilpin CJ, et al. Bladder outflow obstruction: a cause of denervation super- sensitivity. J Urol 1987; 138:1461
  11. Boreham PF, Braithwaite P, Milewski P, Pearson H. Alpha-adrenergic blockers in prostatism. Br J Surg. 1977; 64:756. 12.Gerstenberg T, Blaabjerg J, Nielsen ML, Clausen S. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation. Invest Urol 1980; 18:29
  12. Furuya S, Kumamota Y, Yokoyama E, et al. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128:836
  13. Chappie CR, Aubry ML, James S, et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localiza- tion. BrJ Urol 1989; 63: 487
  14. Breslin D, Fields DW, Chou TC, et al. Medi